Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Bristol Myers Squibb is shifting its Alzheimer’s research strategy beyond amyloid-targeting therapies because decades of amyloid-focused trials have delivered disappointing results relative to their enormous research investment. While some amyloid-targeting drugs like lecanemab have shown modest slowing of cognitive decline in early-stage patients, they do not reverse or halt disease progression meaningfully for most people. The company recognizes that Alzheimer’s disease involves multiple pathological processes—including tau tangles, neuroinflammation, mitochondrial dysfunction, and neurodegeneration—and targeting amyloid alone addresses only one piece of a far more complex puzzle.
This strategic pivot reflects a hard-won lesson from the entire industry: a disease as heterogeneous and multifactorial as Alzheimer’s requires combination approaches and alternative biological targets. Bristol Myers Squibb has acquired and developed programs focused on tau pathology, neuroinflammatory mechanisms, and other non-amyloid pathways. For instance, their research into tau-targeting therapies acknowledges that tau tangles accumulate and spread through the brain independently of amyloid, causing significant neuronal damage in many patients who show no amyloid pathology at all.
Table of Contents
- Why the Amyloid Hypothesis Alone Has Not Solved Alzheimer’s
- Tau Tangles and Neuroinflammation as Primary Disease Drivers
- Bristol Myers Squibb’s Multi-Targeted Research Portfolio
- Clinical Evidence Supporting Non-Amyloid Pathways in Alzheimer’s
- Challenges in Transitioning Away From Established Pathways
- Early-Stage Programs and Emerging Research Areas
- The Future of Alzheimer’s Drug Development and Bristol Myers Squibb’s Position
- Conclusion
- Frequently Asked Questions
Why the Amyloid Hypothesis Alone Has Not Solved Alzheimer’s
The amyloid cascade hypothesis dominated Alzheimer’s research for nearly three decades, yet clinical translation has been remarkably slow. Out of more than 400 Alzheimer’s drug candidates tested in clinical trials since 2000, the vast majority targeting amyloid as a sole mechanism failed to slow cognitive decline or showed only marginal benefit. Solanezumab, bapineuzumab, and numerous other anti-amyloid monoclonal antibodies were discontinued after expensive Phase 3 failures, representing billions in sunk research costs. Lecanemab, approved in 2023, slowed cognitive decline by approximately 35% over 18 months in early symptomatic amyloid-positive patients—a statistically significant result, but one that translates to roughly 4.5 months of delayed cognitive decline, prompting many neurologists to question whether the modest effect justifies the weekly infusions, PET scans, and risk of amyloid-related imaging abnormalities (ARIA) including microhemorrhages.
A critical limitation of amyloid-targeting approaches is that amyloid pathology alone does not predict who will develop dementia or how quickly cognitive decline will occur. Autopsies and imaging studies consistently show that 30% of cognitively normal older adults have significant amyloid accumulation in their brains with no dementia symptoms, while some people with advanced dementia show minimal amyloid pathology. This disconnect suggests that amyloid is neither necessary nor sufficient to cause cognitive decline in all Alzheimer’s patients—a finding that fundamentally challenges the foundation of decades of pharmaceutical research strategy. Bristol Myers Squibb’s decision to diversify its pipeline acknowledges this biological reality.
Tau Tangles and Neuroinflammation as Primary Disease Drivers
While amyloid sits in plaques between neurons, tau protein forms neurofibrillary tangles inside neurons and is widely believed to be more directly toxic to neural tissue. Tau tangles spread through the brain in patterns that correlate more strongly with cognitive decline than amyloid deposition does, and tau accumulation occurs in the brains of people with Alzheimer’s variants that show little or no amyloid pathology, such as primary age-related tauopathy (PART). Bristol Myers Squibb has invested in tau-targeted therapies recognizing that blocking tau pathology may provide clinical benefit for a broader population than amyloid-targeting drugs reach.
Neuroinflammation—the chronic activation of microglia and astrocytes in response to protein misfolding and neurodegeneration—is increasingly recognized as a key driver of neuronal death in Alzheimer’s disease. Amyloid and tau both trigger inflammatory responses, but the inflammatory cascade can persist and cause independent damage even after primary pathogenic proteins are cleared. A significant limitation of current neuroinflammatory therapies is that they must be deployed early in disease progression before widespread neuronal loss has occurred; by the time someone has advanced dementia, inflammation may be a secondary phenomenon and anti-inflammatory strategies may offer little cognitive benefit. Bristol Myers Squibb’s work in this space targets specific inflammatory pathways, including TLR4 and NLRP3 inflammasome inhibition, which may prevent the spread of neurodegeneration even in later-stage patients.
Bristol Myers Squibb’s Multi-Targeted Research Portfolio
Bristol Myers Squibb has assembled a diverse pipeline addressing Alzheimer’s through multiple biological mechanisms acquired through strategic acquisitions and internal development. The company’s acquisition of Inhibrx brought tau-targeting therapies into its portfolio, while partnerships and acquisitions focused on neuroinflammatory pathways have expanded its depth in this area. Rather than betting the company on a single mechanism like amyloid, Bristol Myers Squibb is pursuing what researchers call a “multi-hit” strategy—the idea that simultaneous targeting of amyloid, tau, inflammation, and synaptic dysfunction may produce additive or synergistic benefits that single-target approaches cannot achieve.
One concrete example of this portfolio approach is the company’s investigation of combination therapies in preclinical models, where targeting both amyloid and tau simultaneously produces greater neuronal protection than targeting either pathway alone. The rationale is straightforward: if amyloid triggers tau pathology, and both proteins drive inflammation, then blocking all three pathways simultaneously—perhaps at different stages of disease—might prevent a cascade of neurodegeneration that single-target drugs cannot halt. A key tradeoff of this approach is added complexity: combination therapies are harder to develop, require longer clinical trials to demonstrate safety and efficacy, face more regulatory scrutiny, and are inherently more expensive to manufacture and distribute than single-agent medicines.
Clinical Evidence Supporting Non-Amyloid Pathways in Alzheimer’s
Emerging clinical data from non-amyloid-targeted trials is beginning to validate Bristol Myers Squibb’s strategic shift. Tau-PET imaging studies show that tau accumulation in specific brain regions—particularly the medial temporal lobe and cortex—predicts cognitive decline more robustly than amyloid burden in many patient subgroups. A comparison of tau-PET and amyloid-PET imaging in large cohorts reveals that while amyloid spreads relatively diffusely throughout the brain and can be present without symptoms, tau spreads in networks that align with vulnerable circuits for memory and executive function.
This neurobiological evidence directly supports targeting tau as a primary mechanism rather than merely an amyloid-driven consequence. Neuroinflammatory biomarkers in cerebrospinal fluid and blood, including phosphorylated tau species (p-tau181, p-tau217), neurofilament light chain, and glial activation markers, are increasingly recognized as early indicators of neurodegeneration and predictors of future cognitive decline. Some of these markers appear to rise before amyloid accumulation becomes detectable, suggesting that inflammation and synaptic dysfunction may initiate pathology rather than follow amyloid accumulation. For patients with these biomarker profiles, amyloid-targeting therapies alone may offer limited benefit, whereas anti-inflammatory strategies, tau-targeted approaches, or neuroprotective agents might be more appropriate—a clinical reality that justifies Bristol Myers Squibb’s diversified investment strategy.
Challenges in Transitioning Away From Established Pathways
Shifting focus away from amyloid presents substantial scientific and commercial challenges that slow Bristol Myers Squibb’s progress despite strategic necessity. Amyloid-targeting drugs have the advantage of decades of regulatory precedent, established biomarker validation through PET imaging, and demonstrated (albeit modest) clinical benefit in defined patient populations. In contrast, tau-targeted therapies lack comparable clinical proof-of-concept in humans, tau-PET imaging is less standardized than amyloid-PET, and the correlation between tau burden and cognitive symptoms is more complex than initially believed—some people with high tau burden remain cognitively intact, requiring precision medicine approaches to identify who will actually benefit from tau-targeted drugs. A critical limitation of non-amyloid approaches is the difficulty of validating them in clinical trials.
Amyloid-PET is a standardized biomarker that most major medical centers can perform and interpret; tau-PET is less widely available and more heterogeneous across different tracer compounds. Without reliable biomarkers, patient selection for tau-targeted trials is challenging, potentially leading to negative results or inflated effect sizes in small responder populations. Bristol Myers Squibb must invest in biomarker development, imaging infrastructure, and validation studies before advancing non-amyloid therapies into late-stage trials—a costly and time-consuming process that competes with more immediately profitable research directions. Additionally, if a non-amyloid therapy ultimately fails in Phase 3 trials, the company will have diverted resources from potentially productive amyloid programs without generating regulatory approval or market revenue.
Early-Stage Programs and Emerging Research Areas
Bristol Myers Squibb’s research into microglial activation and astrocyte dysfunction represents an emerging frontier in Alzheimer’s therapeutics. Microglia, the resident immune cells of the brain, are increasingly understood to play dual roles—protective in early disease when they clear amyloid and tau, but harmful in chronic disease when they produce pro-inflammatory cytokines and contribute to neuronal death. Targeting microglial overactivation through colony-stimulating factor 1 receptor (CSF1R) inhibition is being explored, though a significant limitation is that excessive microglial suppression may impair the brain’s ability to clear misfolded proteins and repair damage. Early data suggest a narrow therapeutic window where some microglial activation is beneficial but chronic excessive activation is harmful.
Another emerging area is mitochondrial dysfunction and metabolic dysregulation in Alzheimer’s disease. Many neurons in Alzheimer’s brains show mitochondrial stress, impaired energy metabolism, and reduced ATP production, which may underlie synaptic loss and neuronal death independent of amyloid and tau. Bristol Myers Squibb and other companies are exploring mitochondrial-targeted antioxidants and metabolic enhancers, though clinical translation remains early and the specificity of such approaches is uncertain. For example, the observation that certain antioxidant therapies have failed in previous Alzheimer’s trials suggests that simply reducing oxidative stress is insufficient; the company must identify whether specific mitochondrial pathways are actionable targets or whether mitochondrial dysfunction is a secondary consequence of amyloid and tau pathology that resolves only when primary drivers are addressed.
The Future of Alzheimer’s Drug Development and Bristol Myers Squibb’s Position
The trajectory of Alzheimer’s therapeutics is moving toward personalized, multi-target approaches that require early diagnosis and biomarker-guided patient selection. Future treatments may resemble cancer therapy—where different patient subtypes receive combination regimens targeting their specific pathological drivers—rather than single-agent monotherapies for all diagnosed patients. Bristol Myers Squibb is positioned to capitalize on this shift through its diverse pipeline, but success will depend on clinical trials demonstrating that non-amyloid targets deliver clinically meaningful cognitive benefits, that combination approaches outperform single agents, and that biomarker-guided patient selection identifies populations likely to benefit.
Looking forward, the next decade of Alzheimer’s research will likely determine whether Bristol Myers Squibb’s diversification strategy was prescient or premature. If tau-targeted or neuroinflammatory therapies prove ineffective, the company may have diverted resources from amyloid programs unnecessarily. Conversely, if combination therapies targeting multiple pathways demonstrate superior cognitive outcomes compared to current amyloid-only approaches, Bristol Myers Squibb’s early investment in non-amyloid mechanisms may yield a competitive advantage and establish new standard-of-care treatment paradigms for the millions of people living with Alzheimer’s disease globally.
Conclusion
Bristol Myers Squibb is looking beyond amyloid in Alzheimer’s research because amyloid-targeting drugs alone have consistently delivered marginal clinical benefit despite enormous investment, and a growing body of biological and clinical evidence demonstrates that tau, neuroinflammation, and mitochondrial dysfunction are independent disease drivers requiring targeted intervention. The company’s pivot toward multi-targeted therapies reflects scientific maturity in recognizing that Alzheimer’s is not a single-pathology disease but rather a syndromic condition where different patients may have different primary drivers of neurodegeneration and may respond differently to targeted interventions.
For people living with dementia and their families, this strategic shift offers hope that future treatments will be more effective and better-tailored to individual disease biology than current amyloid-focused therapies. However, translating these scientific insights into clinically available medications will require successful Phase 2 and Phase 3 trials demonstrating that non-amyloid approaches improve outcomes, careful patient selection using biomarkers, and ultimately regulatory approval of drugs acting through novel mechanisms. In the near term, people with early-stage Alzheimer’s should discuss both amyloid-targeted treatments and the emerging research landscape with their neurologist to make informed decisions about their participation in clinical trials testing next-generation therapeutics.
Frequently Asked Questions
If amyloid targeting has failed so many times, why did lecanemab get approved?
Lecanemab showed a 35% slowing of cognitive decline in early symptomatic amyloid-positive patients—a modest but statistically significant effect that met regulatory standards. However, the benefit is limited to people in the earliest stages of cognitive symptoms and those with confirmed amyloid pathology. The modest effect size and requirement for weekly infusions have led many patients and physicians to question whether the benefit justifies the burden and risks, which is why amyloid targeting alone is increasingly viewed as insufficient.
What is tau and why is it more important than amyloid?
Tau is a protein that abnormally accumulates inside neurons as twisted tangles, causing direct cellular toxicity and neural death. Tau tangles correlate more strongly with cognitive decline and memory loss than amyloid does, and they spread through the brain in patterns that affect memory and executive function. Tau is not necessarily “more important” than amyloid—rather, it is a distinct pathological process that must be addressed independently to achieve meaningful cognitive benefit.
Can I get a tau-targeting drug today?
No tau-targeting drugs have achieved regulatory approval yet. Bristol Myers Squibb and other companies have tau-directed therapies in clinical trials, but these are not yet available outside research settings. If you are interested in accessing investigational tau-targeted therapies, ask your neurologist about clinical trial opportunities in your area.
How long until non-amyloid Alzheimer’s drugs reach patients?
Development timelines are uncertain, but most tau-targeted drugs in early clinical testing are likely 5–10 years away from potential regulatory approval, assuming they demonstrate clinical benefit in ongoing trials. Some neuroinflammatory therapies may reach patients sooner. Talk with your healthcare team about current clinical trials if you wish to access promising investigational treatments today.
Why not just treat everyone with multiple drugs targeting amyloid, tau, and inflammation at once?
Combination therapies are more complex to develop, require longer and more expensive clinical trials, carry higher risks of drug interactions or unexpected side effects, and are costlier to manufacture and distribute. Importantly, it is unclear whether all three targets must be addressed in every patient or whether personalized combination approaches targeting individual pathology profiles will be more effective and safer than universal multi-drug regimens. Clinical evidence will guide these decisions.
Should I worry that amyloid-targeting drugs are becoming obsolete?
No. Lecanemab and other amyloid-targeting drugs will likely remain part of Alzheimer’s treatment for many years as part of combination regimens or for specific patient populations. However, amyloid targeting alone is increasingly recognized as insufficient for most patients, so future treatments will probably combine amyloid-targeting with other approaches rather than replacing amyloid drugs entirely.
